Aurora Cannabis Inc. (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) and CTT Pharmaceutical Holdings Inc. ("CTT") (US-OTC: CTTH) today announced that Aurora is acquiring an initial 9.14% ownership interest in CTT via way of a non-brokered private placement in the form of a US$1 million 5% convertible debenture.
Cronos Group Inc. (NASDAQ, TSX-V: CRON), a geographically diversified and vertically integrated cannabis group, announced today it has appointed Jim Rudyk as lead director and has entered into an engagement agreement to retain Athena Advisors LLC as its agency of record for investor relations and corporate communications.
Today Choom has announced 3 additions to their Board of Advisors, and safe to say, they are definitely heavyweights.
Canopy Rivers Corporation is excited to help foster growth in the Canadian cannabis landscape by hosting a pitch day for cannabis entrepreneurs ahead of impending adult use legalization. In accordance with the proposed regulations underneath the Cannabis Act (Bill C-45) and the new "micro" class of licenses, the Company is offering up to $1,000,000 of seed capital to support a diverse range of aspiring cannabis entrepreneurs.
CannTrust Holdings Inc. (TSX:TRST), a licensed producer of medical cannabis under the Health Canada Access to Cannabis for Medical Purposes Regulation program, today announced that it has entered into an agreement with a syndicate of underwriters led by Canaccord Genuity Corp. and GMP Securities L.P., pursuant to which the Underwriters will purchase, on a bought deal basis pursuant to the filing of a short form prospectus, an aggregate of 8,350,000 units of the Company at a price of $9.00per Unit for aggregate gross proceeds of $75,150,000.
CanopyVentures™, a venture capital firm investing in companies providing value throughout the legal cannabis supply chain, today announced an investment of $750,000 in BDS Analytics, the cannabis industry's leader in comprehensive, actionable, and accurate market intelligence and consumer research. The Series B funding for BDS Analytics marks Canopy's first investment through Canopy Ventures I, the firm's $50 million venture fund targeting growth stage companies.
Choom secured the rights to an additional 8 retail locations in Alberta, giving them a total of 17 applications in the approval process with the Alberta Gaming and Liquor Commission (AGLC).
Active cannabis stocks in the markets include: Choom™ Holdings Inc. (CSE: CHOO) (OTC: CHOOF), Canopy Growth Corporation (TSX: WEED) (OTC: TWMJF), Newstrike Resources Ltd. (TSX-V: HIP) (OTC: NWKRF), The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTC: TGODF), Hiku Brands Company Ltd. (CSE: HIKU) (OTC: DJACF).
Canopy Growth Corporation (TSX: WEED) announced today it has applied to list its common shares on the New York Stock Exchange.
Cannabis Wheaton Income Corp. (TSX-V:CBW) is pleased to announce that it has entered into a definitive licensing agreement with Dixie Brands, Inc. pursuant to which Cannabis Wheaton will have the exclusive license to Dixie’s intellectual property, product branding and formulation methodologies related to over 100 cannabinoid-infused products in Canada and Mexico.
Aurora Cannabis Inc.(TSX: ACB) and MedReleaf Corp. (TSX: LEAF) are pleased to announce that they have entered into a definitive arrangement agreement whereby Aurora intends to acquire all of the issued and outstanding common shares of MedReleaf in an all-share transaction valued at approximately C$3.2 billion on a fully diluted basis.
InMed Pharmaceuticals Inc. (TSX:IN; OTCQX:IMLFF), today announced it has filed a Patent Cooperation Treaty application for INM-085 as a cannabinoid-based topical therapy for glaucoma, which includes protection of its technology in about 150 different countries including the United States, and claims a priority date from May 8, 2018 (PCT/CA2018/050548).
InMed Pharmaceuticals Inc. (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and biosynthesis platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today reported financial results for the three and nine months ended March 31, 2018, which is the Company's third quarter of fiscal year 2018 ("3Q18").
Following the satisfaction of the escrow release conditions, $34.6 millionwere released from escrow to Alcanna.
Beleave Inc. (CSE: BE) (OTCQX: BLEVF) is pleased to announce that it has completed the construction and commissioning of a new state-of-the-art industrial extraction laboratory at its production facility located in Hamilton, Ontario.
